HUMAN RECOMBINANT INSULIN MARKET ANALYSIS

Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022
Code : CMI1797
Pages :205
Formats :
Excel and PDF
Industry : Biotechnology

Market News

Global Human Recombinant Insulin Market: Key Developments

On April 26, 2022, Biologics Limited (BBL), a subsidiary of Biocon Ltd., announced that its subsidiary Biocon Sdn. Bhd. in Malaysia has been awarded a three-year contract, valued at US$ 90 million, for company's recombinant human insulin brand Insugen by the Ministry of Health (MoH), Malaysia.

}